Slingshot members are tracking this event:
Phase 3 data of Cimzia (certolizumab pegol) for Moderate-to-severe plaque psoriasis due by end of 1Q 2017
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|DERM||Community voting in process|
Slingshot Insights Explained
Jan 19, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Data, Cimzia, Plaque Psoriasis, Certolizumab Pegol